Core Insights - The Chemours Company reported a net loss of $386 million for the full year 2025, compared to a net income of $69 million in 2024, primarily due to litigation-related charges and lower pricing in the Titanium Technologies segment [1][3][5] - Adjusted EBITDA for 2025 was $742 million, a decrease from $768 million in the previous year, reflecting challenges in pricing and production levels [1][3][5] - The company anticipates consolidated net sales growth of 3% to 5% for 2026, driven by increased demand in Thermal & Specialized Solutions and Advanced Performance Materials [1][3][5] Fourth Quarter 2025 Results - Net sales for Q4 2025 were $1.3 billion, down 2% year-over-year, with a notable 37% growth in Opteon™ Refrigerants [1][2] - Adjusted EBITDA for Q4 2025 was $128 million, a decline of 24% from $168 million in Q4 2024 [1][2] - The net loss attributable to Chemours in Q4 2025 was $47 million, compared to a loss of $11 million in the same quarter of the previous year [1][2] Segment Performance Thermal & Specialized Solutions (TSS) - TSS reported Q4 2025 net sales of $444 million, a 14% increase year-over-year, driven by a 10% price increase and a 3% volume increase [2][3] - Full year 2025 net sales for TSS reached a record $2.1 billion, up 13% from 2024, with Opteon™ Refrigerants growing by 56% [2][3] Titanium Technologies (TT) - TT's Q4 2025 net sales were $561 million, an 11% decrease compared to Q4 2024, primarily due to a 6% decrease in pricing [2][3] - Full year 2025 net sales for TT were $2.4 billion, down 6% from the previous year, attributed to weaker demand and pricing [2][3] Advanced Performance Materials (APM) - APM's Q4 2025 net sales were $312 million, a 4% decrease year-over-year, driven by an 8% decline in volume [2][3] - Full year 2025 net sales for APM were $1.3 billion, down 5% from 2024, reflecting weaker global demand [2][3] Financial Outlook - The company expects free cash flow conversion to exceed 25% in 2026, with adjusted EBITDA projected between $800 million and $900 million [1][3] - Capital expenditures for 2026 are anticipated to range from $275 million to $325 million, with a focus on improving cash flow and debt profile [1][3]

Core Viewpoint - The Chemours Company (NYSE:CC) is recognized as one of the Best Small Cap Value Stocks to Buy, with a share price increase of over 12% since its fiscal Q3 2025 results, despite subpar earnings and a mixed outlook from Wall Street [1]. Financial Performance - In fiscal Q3 2025, Chemours reported a 0.40% year-over-year decrease in revenue to $1.50 billion, falling short of expectations by $2.98 million [3]. - The earnings per share (EPS) of $0.20 was below analysts' consensus by $0.04 [3]. - The decline in revenue was primarily due to a 36% decrease in net sales of Freon Refrigerants and a 16% decrease in net sales of Foam, Propellants & Other [3]. - This negative performance was partially offset by an 80% year-over-year increase in net sales of Opteon™ Refrigerants, which reached $560 million [3]. Analyst Ratings and Price Targets - J.P. Morgan's Jeffrey Zekauskas reiterated a Hold rating on Chemours and lowered the price target from $15 to $13 [2]. - Alembic Global's Hassan Ahmed also lowered the price target from $20 to $19 while maintaining a Buy rating [2]. Market Challenges and Management Response - Analysts at Truist Financial noted demand challenges in the Titanium Technologies and industrial markets within Advanced Performance Materials [4]. - Despite these challenges, analysts expressed confidence in management's efforts to right-size production and preserve cash flow under tough market conditions [4]. Company Overview - Chemours provides performance chemicals and delivers solutions across various markets, including plastics, semiconductors, consumer electronics, coatings, transportation, refrigeration and air conditioning, and general industrial [5].